Uncategorized

  • Isofol presents an abstract at ASCO GI in January 2021

    Isofol announces that an abstract, including arfolitixorin in the ISO-CC-005 study, has been accepted to be presented at ASCO GI…

    by
  • Invitation to a conference call and webcast by Isofol in connection with the entered license agreement for Paladin Labs Inc. to commercialize arfolitixorin in Canada

    GOTHENBURG, Sweden, November 2, 2020 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) has today…

    by
  • Presentation and poster at ASCO Gastrointestinal Cancers Symposium

    Isofol is attending the event and will present details in the ongoing global Phase 3 AGENT clinical study (ISO-CC-007) Presentation…

    by
  • Isofol Announces Recent Advisory Board Meeting Covering Development Plan for arfolitixorin

    Isofol Announces Recent Advisory Board Meeting Covering Development Plan for arfolitixorin GOTHENBURG, Sweden, July 15, 2019 – Isofol Medical AB…

    by